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Cardiovascular response to hemodialysis: The effects of uremia
and dialysate buffer. Cardiovascular instability continues to be
one of the primary clinical problems in hemodialysis. Acetate
buffer in dialysate is one of the factors that may induce hypoten-
sion. Since uremia may have a direct effect on the regulation of
the cardiovascular system, the present study was designed to
investigate the separate effects of uremia and acetate hemodial-
ysis on blood pressure in anesthesized dogs, as well as the
hemodynamic parameters determined by invasive cardiovascular
monitoring. Animals were separated into four groups: (1) group I,
hemodialysis with acetate in controls; (2) group II, hemodialysis
with acetate in uremic dogs; (3) group III, hemodialysis with
bicarbonate in controls; and (4) group IV, hemodialysis with
bicarbonate in uremic dogs. Acute uremia was induced by bilat-
eral ureteral ligation and a 90-minute hemodialysis (acetate or
bicarbonate) procedure was performed 72 hours later. The results
obtained in this study show that, compared with dogs with normal
renal function, acute uremia resulted in an elevation in mean
arterial pressure (MAP; 178 6 13 vs. 115 6 23 mm Hg, P , 0.01),
which was associated with an increase in cardiac index (CI) and
left ventricular stroke work index (LVSWI). In these dogs, the
pulmonary capillary wedge pressure (PCWP; preload) and the
systemic vascular resistance index (SVRI; afterload) were not
different than controls. In uremic dogs, hemodialysis with acetate,
but not with bicarbonate, decreased the MAP to values similar to
controls. The decrease in MAP induced by acetate hemodialysis in
uremic dogs was associated with a decrease in SVRI and PCWP.
These results suggest that in dogs with acute uremia, acetate
hemodialysis (HD) decreases miocardial contractility that was
previously increased by a direct effect of uremia. In controls,
acetate produced a moderate decrease in MAP that was the result
of a mild decrease in CI and SVR. Since PCWP was not
significantly decreased after acetate HD, the decrease in CI can be
attributed to a mild decrease in myocardial performance. In
conclusion, this study in dogs suggests that uremia enhances
myocardial contractility directly. Acetate hemodialysis reduces
this elevated miocardial contractility to normal values.
Cardiovascular instability continues to be one of the
main clinical problems in hemodialysis [1]. Hypotension
during hemodialysis has been attributed to a combination
of factors: a decrease in plasma osmolality [2], volume
depletion [3], impairment of sympathetic autonomic re-
sponse [4, 5], myocardial diastolic dysfunction [6] and the
use of acetate [1, 5]. Acetate-induced hypotension has been
explained by vasodilation due to a direct effect on vascular
smooth muscle [7, 8] and by a decreasing myocardial
contractility [9–12]. However, the results reported on the
myocardial depressant effects of acetate have not been
consistent; some authors have found no myocardial impair-
ment during hemodialysis using acetate as compared to
bicarbonate [13, 14]. Since uremia may have a direct effect
in the regulation of the cardiovascular system, the role of
acetate as a factor inducing cardiovascular instability must
be analyzed in the setting of uremia. We consider that the
effect of acetate on a cardiovascular system may not be the
same in an uremic environment as in normal renal function.
The aim of this study was to investigate in anesthesized
dogs the separate effects of uremia and acetate hemodial-
ysis on blood pressure and the hemodynamic parameters
that can be determined by invasive cardiovascular monitor-
ing.
METHODS
Animal model
The experiments were performed in 28 adult mongrel
dogs (20 to 32 kg). Half of the animals underwent bilateral
ureteral ligation and the other half were sham-operated.
Seventy-two hours later the animals were assigned to four
groups of seven dogs each: (1) group I, hemodialysis with
acetate in controls; (2) group II, hemodialysis with acetate
in uremic dogs; (3) group III, hemodialysis with bicarbon-
ate in controls; and (4) group IV, hemodialysis with bicar-
bonate in uremic dogs.
Hemodialysis procedure
The animals were allowed free access to water but not
food during the 12 hours preceding the experiment. Anes-
thesia was induced by intravenous administration of sodium
penthobarbital (15 mg/kg body wt) and maintained with a
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combination of pancuronium bromide (0.1 mg/kg body wt),
fentanyl (0.05 mg/kg body wt), and midazolam (0.2 mg/kg
body wt). An endotracheal tube was placed and ventilation
was maintained using a volumetric respirator (MA-2 Puri-
tan Bennett, Los Angeles, CA, USA). The ventilatory
parameters were: tidal volume, 15 ml/kg/body wt; FiO2 5
0.5, PEEP 5 5 cm H2O; respiratory rate between 12 to 15
rpm to maintain the PaCO2 at 32 to 35 mm Hg.
The femoral artery and vein were used as vascular access
for hemodialysis. Blood and dialysate flow rates were 100
and 500 ml/min, respectively. The hemodialysis period was
90 minutes, there was no ultrafiltration, and the membrane
used was cuprophan 0.7 m2. Anticoagulation was achieved
with a pre-hemodialysis i.v. bolus of sodium heparin 100
IU/kg. The composition (mEq/liter) of the dialysate was:
sodium 138, potasium 4 and acetate 35 for the acetate
dialysate; and the same sodium and potassium concentra-
tion, with bicarbonate 35 and acetate 2.75, for the bicar-
bonate dialysate.
Hemodynamic measurements
An indwelling catheter was inserted into the contralat-
eral femoral artery for blood pressure monitoring and
blood sampling. A triple lumen Thermodilution Swan-
Ganz catheter (Edwards Laboratories AHS, An˜asco,
Puerto Rico, USA) was inserted through an upper limb
vein and advanced into the main pulmonary artery. Both
the Swan-Ganz and the arterial catheters were connected
to pressure transducers (model 21080A; Hewlett-Packard,
Palo Alto, CA) previously placed at the level of the middle
right atrium. Pressure measurements and ECG were re-
corded using a four-channel amplifier (model 7754B;
Hewlett-Packard). Cardiac output (CO) was measured by a
thermodilution technique (Cardiac output computer model
9520; Edwards Laboratories). Each value represented the
mean of three consecutive measurements.
The following parameters were measured at baseline and
at 15 minute intervals: blood pressure, heart rate (HR),
pulmonary capillary wedge pressure (PCWP), cardiac out-
put (CO) and central venous presssure (CVP).
The following hemodynamic and pulmonary function
parameters were calculated based on previously published
formulas [15, 16]: mean arterial pressure (MAP), cardiac
index (CI), systolic index (SI), left ventricular stroke work
index (LVSWI), systemic vascular resistance index (SVRI).
Body surface area (BSA) was calculated using the formula:
BSA 5 0.112 3 3=(weight)2 [17].
Blood sample measurements
Blood samples were drawn from the femoral artery at
baseline and at 15 minute intervals to test the following:
total protein, creatinine, BUN, sodium and potassium by
autoanalyzer; acetate concentration by an enzymatic tech-
nique using a kit from Boehringer Manheim, Germany;
osmolality by freezing point depression (Fiske Os Osmom-
eter; Beckman, Germany); and blood gases (Radiometer,
ABL-2, Copenhagen, Denmark). Plasma volume was mea-
sured before and after completing hemodialysis using 131I-
albumin from Sorin Biomedica (Mirandola, Italy).
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care,” formulated by the
National Society for Medical Research and the “Guide for
the Care and Use of Laboratory Animals,” prepared by the
National Academy of Science and published by the Na-
tional Institutes of Health (NIH publication No 86-23,
revised 1985).
Statistical methods
The results are expressed as the mean 6 SE. Comparisons
between two means were made by a non-paired t-test.
ANOVA followed by Scheffe´’s test was used for multiple
comparisons. Statistical significance was defined as P ,
0.05.
RESULTS
Compared to controls, uremic dogs showed significantly
higher values of serum creatinine, osmolality, potassium
and total protein. The serum bicarbonate levels were lower
in uremic than in control dogs (Table 1). The weight was
similar in both groups, and the measured plasma volume
was moderately decreased in uremic as compared to con-
trol dogs, although the difference was not statistically
significant.
Baseline hemodynamic parameters for control and ure-
mic dogs are given in Figure 1. MAP was markedly
increased in uremic dogs as compared to controls (178 6 13
vs. 115 6 23 mm Hg, P , 0.01). This increase in MAP in
uremic dogs was associated to a significant elevation of CI
(2.75 6 0.51 vs. 4.09 6 0.82 liter/min/m2 P , 0.05), with no
differences in PCWP. The LVSWI was greater in uremic
than in control dogs (70.4 6 17 vs. 33.3 6 11 g/m/m2 P ,
0.05) and the SVRI did not significantly differ in both
groups (3674 6 869 vs. 4194 6 648 dyn 3 sec/cm5, NS in
control and uremic dogs, respectively).
Changes in MAP, CI and SI during acetate and bicar-
bonate hemodialysis in control and uremic dogs are shown
in Figure 2A.
Table 1. Basal parameters in control and uremic dogs
Control Uremia P
Creatinine mg/dl 0.69 6 0.25 11.53 6 0.95 , 0.05
Osmolarity mOsm 296 6 3 336 6 4 , 0.05
Sodium mEq/liter 140 6 4 139 6 3 NS
Potassium mEq/liter 3.51 6 0.34 5.9 6 0.73 , 0.05
Total protein g/liter 5.1 6 0.3 6.5 6 0.4 , 0.01
Bicarbonate mEq/liter 20.0 6 3 17.5 6 2.25 , 0.05
Weight kg 21 6 1 24.1 6 4 NS
Plasma volume ml 1973 6 288 1693 6 353 NS
NS is not significant.
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Mean arterial pressure
Bicarbonate hemodialysis did not result in a significant
change in MAP in control dogs. In uremic dogs, bicarbon-
ate hemodialysis caused a moderate decrease in blood
pressure, but the MAP values at the end of HD were still
high (167 6 7 mm Hg). By contrast, acetate HD resulted in
a marked decrease in MAP in uremic dogs (from 174 6 15
to 98 6 29 mm Hg, P , 0.01). In controls, acetate HD also
led to a significant decrease in MAP (from 120 6 18 to
92 6 27 mm Hg, P , 0.01). The MAP decrease induced by
acetate HD was greater in uremic than control dogs, and at
the end of the HD procedure MAP values in uremic and
control dogs were similar.
Cardiac index
As seen for MAP, bicarbonate HD did not induce a
significant change in CI in control dogs, while in uremic
dogs it caused only a moderate decrease in CI that did not
reach statistical significance. In uremic dogs that had high
baseline CI values acetate HD decreased CI to almost half
compared to baseline; however, these values of CI after
acetate HD were similar in uremic and control dogs. In
controls, acetate HD caused a moderate increase in CI at
15 minutes that did not reach statistical significance, and at
the end of hemodialysis the values were similar to baseline.
Systolic index
Bicarbonate HD did not significantly change SI in con-
trol and uremic animals. Acetate HD caused changes in SI
similar to those observed in CI, while in uremic dogs
acetate HD decreased the SI to half the initial values. In
controls, acetate HD resulted in a moderate increase in SI
at 15 minutes, followed by a progressive decrease until the
end of HD, at which time values were not different from
baseline. SI values after acetate HD were lower in uremic
than in control dogs, but the difference was not statistically
significant.
Changes in SVR, PCWP, and LVSWI during acetate and
bicarbonate hemodialysis in controls and uremic dogs are
shown in Figure 2B.
Systemic vascular resistance index
During bicarbonate HD, the SVRI did not change in
uremic and control dogs. Acetate HD induced an initial (15
min) fall in SVRI in the control group that was not
statistically significant by one-way ANOVA. In uremic
animals, the SVRI did not significantly change during
acetate HD.
Pulmonary capillary wedge pressure
During bicarbonate HD, the PCWP remained un-
changed in the control and uremic groups. In control dogs
undergoing acetate HD, the PCWP tended to remain
moderately elevated, but the difference was not statistically
significant compared to baseline values. However, by the
end of the procedure the values were similar to those seen
at baseline, and in uremic animals PCWP did not change
with acetate HD.
Fig. 1. Baseline values for mean arterial
pressure (MAP), left ventricular stroke work
index (LVSWI), cardiac index (CI) and
pulmonary capillary wedge pressure (PCWP) in
control (non-uremic) and uremic dogs. Values
are mean 6 SE; *P , 0.05.
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Left ventricular stroke work index
Bicarbonate HD did not cause a significant change in
LVSWI controls. In uremic dogs, bicarbonate HD led to a
moderate decrease in LVSWI that was not statistically
significant until the end of the bicarbonate HD. Neverthe-
less, in uremic dogs LVSWI was still higher than in controls
at the end of bicarbonate HD (P , 0.01). By contrast, in
uremic dogs acetate HD induced a relatively rapid decrease
in LVSWI, and the values and the end of the procedure
were similar to those of controls treated with bicarbonate
HD. In controls treated with acetate HD, the LVSWI did
not change significantly.
Fig. 2. (A) Values of mean arterial pressure (MAP), cardiac index (CI), and systolic index (SI) during hemodialysis with acetate (continuous line) and
bicarbonate (dotted line) in uremic (closed circle) and control (open circle) dogs. * P , 0.05 versus 0 minutes. (B) Values of systemic vascular resistance
(SVR), pulmonary capillary wedge pressure (PCWP) and left ventricular stroke work index (LVSWI) during acetate and bicarbonate hemodialysis in
uremic and control dogs. Symbols are the same as in A. *P , 0.05 versus 0 minutes.
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The left ventricular work relative to the corresponding
cardiac filling pressure is a measure of myocardial contrac-
tility. Therefore, the relationship between LVSWI and
PCWP in each group of dogs before and after bicarbonate
and acetate HD is shown in Figure 3. For a mean baseline
PCWP within a relatively narrow range (7 to 11 mm Hg),
the LVSWI was greater in uremic than in control dogs. The
acetate HD caused a marked decrease in LVSWI that was
not associated to a commensurate decrease in PCWP. At
the end of acetate HD, the LVSWI values in uremic and
control dogs were similar. In uremic dogs, bicarbonate HD
caused a very modest decrease in LVSWI compared to the
LVSWI decline induced by acetate HD despite a similar
PCWP. In controls, bicarbonate HD did not induce a
significant change in LVSWI and PCWP, while acetate HD
caused a mild drop in LVSWI despite no significant change
in PCWP. Therefore, in uremic dogs myocardial contrac-
tility was increased compared with controls, and after
acetate HD myocardial contractility decreased to values
that were not different from those of controls after acetate
HD. In control dogs, acetate HD resulted in a modest
decrease in myocardial contractility. Bicarbonate HD has
no significant effect on myocardial contractility.
As expected, serum acetate increased after acetate HD
in control and uremic dogs. Blood pH and serum bicarbon-
ate were decreased after acetate HD as compared with
bicarbonate HD (Table 2). In uremic dogs, serum creati-
nine and osmolality decreased with both bicarbonate and
acetate HD. The degree of change of these parameters was
similar with both types of HD. Both types of HD caused no
significant changes in plasma volume.
DISCUSSION
This study was designed to evaluate in dogs the indepen-
dent effects of uremia and HD with acetate on MAP and
invasive hemodynamic parameters. Uremia was induced by
bilateral ureteral ligation, and the animals were evaluated
72 hours later. Both uremic and control (non-uremic)
animals underwent hemodialysis with acetate, and different
dogs were hemodialyzed with bicarbonate. The results
obtained in this study show that compared with dogs with
normal renal function, those with acute uremia show an
increased MAP that is associated with an increase in CI and
LVSWI. In these dogs, PCWP (preload) and SVRI (after-
load) did not differ from the control values. The mecha-
nism by which acute uremia increases LVSWI is not clear,
because neither preload nor afterload changes explain the
increase in LVSWI. Thus, based on our results, uremia has
a direct positive inotropic effect. It is important to empha-
size that dogs used in the present study had acute uremia,
so that hemodynamic findings may not be comparable to
those seen in chronic uremia. Patients with chronic renal
failure on maintenance dialysis have end organ damage,
which is absent in our dog model of acute uremia. There-
fore, we consider that the specific effect of uremic toxic
products on cardiovascular function should be evaluated in
the setting of acute uremia.
In uremic dogs, hemodialysis with acetate, but not with
bicarbonate, decreased MAP to values similar to those of
control dogs. The decrease in MAP induced by acetate
hemodialysis in uremic dogs was associated with a decrease
in CI and LVSWI and with no significant changes in SVRI
and PCWP. These results suggest that in dogs with acute
uremia, acetate HD decreases myocardial contractility that
was previously increased by a direct effect of uremia. Thus,
the drop in MAP can be explained by a decreased CI with
little or no influence of SVRI.
There were some differences between the effect of
acetate hemodialysis in control and uremic dogs. In con-
trols, acetate caused a slight decrease in MAP, resulting
from a mild decrease in CI and SVR. Since PCWP was not
significantly decreased after acetate HD, the decrease in CI
can be attributed to a slight decrease in myocardial perfor-
mance. In controls, acetate HD caused transient changes in
hemodynamic parameters at 15 minutes that are worth
discussing. Compared to baseline, CI and LVSWI were
increased after 15 minutes, and SVRI was decreased. From
this time point until the end of the procedure, CI and
LVSWI tended to decrease, while SVRI remained un-
changed. These results show that in non-uremic animals the
short-term increase in serum acetate concentration may
cause both a decrease in SVR and an increase in CI, the
latter being secondary to the decrease in afterload. Both
effects have been reported by different authors [14, 18–20].
Bicarbonate HD induced basically no change in the
hemodynamic parameters tested, thus demonstrating that
the hemodialysis procedure per se was not the main cause of
the hemodynamic changes observed. Plasma volume and
osmolality were similar after both types of hemodialyses;
however, pH and serum bicarbonate levels were lower after
Fig. 3. Left ventricular stroke work index (LVSWI) relative to the
pulmonary capillary wedge pressure (PCWP) in control (non-uremic) and
uremic dogs before and after acetate and bicarbonate hemodialysis.
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acetate than bicarbonate hemodialysis. It is unlikely that
this mild decrease in pH induced by acetate hemodialysis
could explain the marked differences in hemodynamic
parameters.
In conclusion, the results of the present study in dogs
with acute uremia suggest that uremia enhances myocardial
contractility directly, and that acetate hemodialysis reduces
the resulting increased myocardial contractility to normal
values.
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APPENDIX
Abbreviations used in this article are: MAP, mean arterial pressure;
PCWP, pulmonary capillary wedge pressure; CVP, central venous pres-
sure; HR, heart rate; CO, cardiac output; CI, cardiac index; LVSWI, left
ventricular stroke work index; SVRI, systemic vascular resistance index;
PEEP, positive end-expiratory pressure; PaO2, arterial O2 partial pres-
sure; HD, hemodialysis.
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Table 2. Acetate hemodialysis in control and uremic dogs
Control Uremic
Acetate Bicarbonate Acetate Bicarbonate
Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD Pre-HD Post-HD
Acetate mEq/liter 0 5.97 6 0.8a 0 0.29 6 0.02a,b 0 6.76 6 0.24a 0 0.27 6 0.02a,b
Osmolarity mOsm/kg 296 6 2.2 290 6 5.4 296 6 3.6 295 6 2.9 336 6 3.2 298 6 3.5a 337 6 3.5 299 6 3.4a
Creatinine mg/dl 0.68 6 0.35 0.51 6 0.08 0.7 6 0.11 0.47 6 0.04a 11.3 6 1.34 6.07 6 0.41a 11.7 6 0.22 6.02 6 0.16a
pH 7.30 6 0.05 7.31 6 0.04 7.31 6 0.05 7.34 6 0.06 7.28 6 0.06 7.23 6 0.01a 7.24 6 0.01 7.29 6 0.02a
Bicarbonate mEq/liter 20.8 6 3.32 17.6 6 2.08a 18.8 6 2.52 22.4 6 2.30a,b 16.5 6 2.70 15.6 6 2.62 18.7 6 0.97 24.6 6 1.52
PO2 mm Hg 120.6 6 20.7 104.7 6 14.6 106 6 18.3 92.7 6 16.7
a,b 96.5 6 19.9 79.8 6 14.4a 96.6 6 3.9 88.7 6 1.5a
Plasma volume ml 1862 6 251 1933 6 256 2084 6 297 2118 6 357 1459 6 224 1472 6 300 1928 6 305 1969 6 284
a P , 0.05 vs. pre-HD
b P , 0.05 vs. acetate
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